Latest articles for News
Conference Coverage
ILC: Europe issues hepatitis C treatment priority list
Conference Coverage
ILC: HCV treatment delays dented efficacy in era before all-oral therapy
Key clinical point: Efficacy diminishes when HCV treatment is delayed, particularly in patients who progress to advanced cirrhosis. Major finding...
News
HCV spike in four Appalachian states tied to drug abuse
Key clinical point: Hepatitis C virus infections more than tripled among young people in Kentucky, Tennessee, Virginia, and West Virginia, and...
Conference Coverage
ILC: Real-world success for all-oral antiviral therapy in HCV-related cirrhosis
Key clinical point: An all-oral antiviral regimen appears effective and safe for most patients with decompensated cirrhosis due to chronic HCV...
Conference Coverage
Consider HCV ‘a cardiovascular risk factor’
Key clinical point: Chronic HCV infection was strongly linked to CV outcome and needs to be considered a CV risk factor. Major finding: Adjusted...
News
Interferon-free antiviral regimens achieve high response rates in HCV
Key clinical point: A 12-week course of oral daclatasvir, asunaprevir, and beclabuvir, with or without ribavirin achieves a high response rate in...
Conference Coverage
ILC: Statins linked to better outcomes in hepatitis C cirrhosis
Key clinical point: Hepatitis C–infected patients with associated cirrhosis had fewer deaths and decompensations when receiving statin treatment....
Conference Coverage
HCV increases general cancer risk
Key clinical point: Chronic hepatitis C virus (HCV) infection raises the risk of all types of cancer, not just liver cancer. Major finding: The...
Conference Coverage
ILC: Unrecognized hepatitis C linked with advanced hepatic fibrosis
Key clinical point: One-fifth of Americans with unrecognized chronic hepatitis C infection likely have advanced hepatic fibrosis. Major finding:...
Conference Coverage
ILC: New single daily pill eradicates hepatitis C
Key clinical point: Once-daily, single-pill combination treatment with grazoprevir and elbasvir for 12 weeks was safe and effective for...